Neuronetics, Inc. (NASDAQ:STIM) Expected to Announce Earnings of -$0.41 Per Share

Equities analysts expect Neuronetics, Inc. (NASDAQ:STIMGet Rating) to post earnings per share (EPS) of ($0.41) for the current quarter, Zacks reports. Two analysts have made estimates for Neuronetics’ earnings. The lowest EPS estimate is ($0.42) and the highest is ($0.40). Neuronetics posted earnings per share of ($0.31) in the same quarter last year, which would indicate a negative year over year growth rate of 32.3%. The firm is scheduled to announce its next earnings report on Monday, January 1st.

On average, analysts expect that Neuronetics will report full-year earnings of ($1.69) per share for the current year, with EPS estimates ranging from ($1.74) to ($1.63). For the next fiscal year, analysts forecast that the company will report earnings of ($1.24) per share, with EPS estimates ranging from ($1.62) to ($0.85). Zacks’ earnings per share averages are an average based on a survey of research analysts that follow Neuronetics.

Neuronetics (NASDAQ:STIMGet Rating) last released its earnings results on Tuesday, March 8th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04. Neuronetics had a negative return on equity of 33.24% and a negative net margin of 56.39%. During the same quarter last year, the company earned ($0.19) EPS.

A number of equities analysts recently weighed in on the company. Zacks Investment Research cut Neuronetics from a “buy” rating to a “hold” rating in a research note on Saturday, March 12th. Piper Sandler dropped their price target on Neuronetics from $10.00 to $9.00 in a research note on Monday, January 3rd. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Neuronetics currently has an average rating of “Buy” and an average price target of $10.06.

In other Neuronetics news, CFO Stephen Furlong sold 17,189 shares of Neuronetics stock in a transaction dated Friday, January 21st. The stock was sold at an average price of $3.62, for a total transaction of $62,224.18. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, major shareholder Cannell Capital Llc bought 22,062 shares of the stock in a transaction on Friday, March 25th. The shares were acquired at an average cost of $2.99 per share, for a total transaction of $65,965.38. The disclosure for this purchase can be found here. In the last ninety days, insiders have acquired 143,970 shares of company stock worth $424,338 and have sold 48,948 shares worth $165,469. Insiders own 4.90% of the company’s stock.

Several institutional investors have recently made changes to their positions in the company. Parametric Portfolio Associates LLC lifted its holdings in shares of Neuronetics by 9.0% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 22,599 shares of the company’s stock valued at $362,000 after buying an additional 1,861 shares during the last quarter. Citigroup Inc. lifted its holdings in Neuronetics by 223.8% in the 3rd quarter. Citigroup Inc. now owns 4,177 shares of the company’s stock worth $27,000 after purchasing an additional 2,887 shares during the last quarter. BNP Paribas Arbitrage SA lifted its holdings in Neuronetics by 66.0% in the 4th quarter. BNP Paribas Arbitrage SA now owns 8,350 shares of the company’s stock worth $37,000 after purchasing an additional 3,320 shares during the last quarter. Trexquant Investment LP lifted its holdings in Neuronetics by 25.5% in the 3rd quarter. Trexquant Investment LP now owns 21,792 shares of the company’s stock worth $143,000 after purchasing an additional 4,422 shares during the last quarter. Finally, Bank of America Corp DE lifted its holdings in Neuronetics by 710.4% in the 2nd quarter. Bank of America Corp DE now owns 8,112 shares of the company’s stock worth $130,000 after purchasing an additional 7,111 shares during the last quarter. Institutional investors and hedge funds own 79.48% of the company’s stock.

NASDAQ:STIM traded down $0.11 during mid-day trading on Monday, reaching $2.90. 121,070 shares of the stock were exchanged, compared to its average volume of 195,609. The business’s fifty day moving average price is $3.11. The company has a market cap of $77.22 million, a price-to-earnings ratio of -2.41 and a beta of 2.35. Neuronetics has a 1-year low of $2.80 and a 1-year high of $17.92. The company has a quick ratio of 6.93, a current ratio of 7.34 and a debt-to-equity ratio of 0.41.

About Neuronetics (Get Rating)

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.

Featured Stories

Get a free copy of the Zacks research report on Neuronetics (STIM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Neuronetics (NASDAQ:STIM)

Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.